Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Obesity

Treatments: Drug: MK0557

Study type: Interventional

Funder types: Industry

Identifiers

NCT00533481

0557-015

2007_615

Details and patient eligibility

About

Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.

Enrollment: 497 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women between the ages of 18-65 who are considered obese (have a body mass index between 30 and 43)

Exclusion criteria

• Subject has high blood pressure or is taking any high blood pressure medicine
• History of psychiatric disorder, stroke, or heart disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Double Blind